These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24517171)

  • 1. Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy.
    Bremer PT; Schlosburg JE; Lively JM; Janda KD
    Mol Pharm; 2014 Mar; 11(3):1075-80. PubMed ID: 24517171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.
    Hwang CS; Bremer PT; Wenthur CJ; Ho SO; Chiang S; Ellis B; Zhou B; Fujii G; Janda KD
    Mol Pharm; 2018 Mar; 15(3):1062-1072. PubMed ID: 29420901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats.
    Li QQ; Luo YX; Sun CY; Xue YX; Zhu WL; Shi HS; Zhai HF; Shi J; Lu L
    J Neurochem; 2011 Dec; 119(6):1271-81. PubMed ID: 21951213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
    Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
    Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability.
    Blake S; Bremer PT; Zhou B; Petrovsky N; Smith LC; Hwang CS; Janda KD
    Mol Pharm; 2021 Jan; 18(1):228-235. PubMed ID: 33301675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
    Chu RS; McCool T; Greenspan NS; Schreiber JR; Harding CV
    Infect Immun; 2000 Mar; 68(3):1450-6. PubMed ID: 10678959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like Receptor 9 Agonists as Adjuvants for Nanoparticle-Based Nicotine Vaccine.
    Hu Y; Smith D; Frazier E; Zhao Z; Zhang C
    Mol Pharm; 2021 Mar; 18(3):1293-1304. PubMed ID: 33497574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.
    Raleigh MD; Pravetoni M; Harris AC; Birnbaum AK; Pentel PR
    J Pharmacol Exp Ther; 2013 Feb; 344(2):397-406. PubMed ID: 23220743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.
    Anton B; Leff P
    Vaccine; 2006 Apr; 24(16):3232-40. PubMed ID: 16494974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
    Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
    Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 agonist adsorbed to alum adjuvant prevents asthma-like responses induced by Blomia tropicalis mite extract.
    Nunes FPB; Alberca-Custódio RW; Gomes E; Fonseca DM; Yokoyama NH; Labrada A; Russo M
    J Leukoc Biol; 2019 Sep; 106(3):653-664. PubMed ID: 31329326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin vaccination via fractional infrared laser ablation - Optimization of laser-parameters and adjuvantation.
    Scheiblhofer S; Strobl A; Hoepflinger V; Thalhamer T; Steiner M; Thalhamer J; Weiss R
    Vaccine; 2017 Mar; 35(14):1802-1809. PubMed ID: 28117172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.
    Robinson C; Baehr C; Schmiel SE; Accetturo C; Mueller DL; Pravetoni M
    Hum Vaccin Immunother; 2019; 15(4):909-917. PubMed ID: 30625019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice.
    Moran MC; Bence AR; Vallecillo MFS; Lützelschwab CM; Rodriguez MG; Pardo R; Goldbaum FA; Zylberman V; Palma SD; Maletto BA; Estein SM
    Res Vet Sci; 2021 Mar; 135():217-227. PubMed ID: 33631456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.
    Krieg AM; Efler SM; Wittpoth M; Al Adhami MJ; Davis HL
    J Immunother; 2004; 27(6):460-71. PubMed ID: 15534490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Clinically Viable Heroin Vaccine.
    Bremer PT; Schlosburg JE; Banks ML; Steele FF; Zhou B; Poklis JL; Janda KD
    J Am Chem Soc; 2017 Jun; 139(25):8601-8611. PubMed ID: 28574716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.